Stem Cell Therapy Decreases Covid Deaths
Several clinical studies report increased patient survival following the intravenous infusion of mesenchymal stem cells (MSCs) during the past year. MSCs block the cytokine storm in the lungs and also regenerate cells and tissues damaged by the COVID-19 virus. MSCs are not vaccines and work differently in the treatment of COVID-19.
Also in White Papers
AlloEx®: A Comprehensive Analysis of Secretomes for Advanced Dermatological Applications
The scientific community is increasingly delving into the nuanced realms of secretomes, due to their nature of cellular communication and potential applications in regenerative medicine. These microscopic entities, which are potential essential players in intercellular signaling and tissue regeneration, have received significant attention for their possible therapeutic potential.
Exosomes Secreted by the Cocultures of Normal and Oxygen–Glucose‐Deprived Stem Cells Improve Post‐stroke Outcome
Emerging stroke literature suggests that treatment of experimentally induced stroke with stem cells offered post-stroke neuroprotection via exosomes produced by these cells. Treatment with exosomes has great potential to overcome the limita- tions associated with cell-based therapies.
Mesenchymal Stem Cell Treatment Prevents Post-Stroke Dysregulation of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
Stem cell treatment is one of the potential treatment options for ischemic stroke. We recently demonstrated a protective effect of human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) in a rat model of ischemic stroke.